Across the nation, there seems to some major buzz about CBD. People seem to be raving about CBD for a variety of reasons: “CBD helps me sleep,” “I use CBD when I fly on an airplane,” “I take CBD oil in my coffee in the morning for pain relief.” Whereas some promote it as a wonder drug, others believe it to be a newfangled snake oil. Rather than pay attention to the rumors, let’s get the skinny on CBD.
What is CBD?
CBD is an abbreviation for cannabidiol, the second most active ingredient in marijuana (cannabis). Many people know marijuana to be potent because of THC in the plant. THC is the psychoactive element of marijuana that makes users “high” after consumption. CBD products, however, have very little to no THC. Instead, cannabidiol offers therapeutic treatment for other body conditions. Essentially some of the healing properties of medical marijuana are available without altering the mind of the consumer.
Why do people use CBD?
People take advantage of CBD’s benefits for a variety of reasons. CBD has been studied for treatment of certain types of epilepsy, even in children. Others use CBD to reduce anxiety and insomnia due its calming effects for some people. CBD inhibits inflammatory responses and neuropathic pain. CBD is known for offering relief to types of pain, including menstrual pain and arthritis. Further studies will reveal other benefits in the future. Dog owners have even been able to reduce Fido’s anxiety with CBD, leading to a market of cannabidiol for dogs.
Is cannabidiol safe?
Some people experience side effects and change their dosage or method of administrating the product. Side effects have been reported, such as are nausea, fatigue and irritability. The supplements are not currently FDA regulated, so it is advised to consult your doctor about taking CBD.
So then, what’s all the buzz on CBD?
The CBD market is growing, and it is important that consumers know how to seek out all Natural CBD Products in United States. Stay away from companies that make hyperbolic claims of its ability to cure terminal diseases. CBD is best known for its therapeutic value for seizures, anxiety, insomnia, and pain relief. As regulators continue researching CBD products, public understanding of CDB’s capabilities will improve.
It is important to find a CBD source you can trust. Not all stores are created equal. We recommend that you find a provider that promotes an all-natural product. We at NRX solutions currently work within the wellness industry to promote the benefits of CBD products, so we’ve done our homework. We only sell products that our customers trust. If you have been thinking about trying CBD products, we encourage you to review our all-natural product listings to choose the right CBD for you.
As we mentioned in our February newsletter, USDA has now issued a broad overview on the implementation of the federal hemp program. They also announced a public webinar listening session On March 13th for hemp stakeholders. Details for attending the webinar have not yet been released.
If you are an NHA member we encourage you to submit your questions or concerns to us as we intend to submit them ahead of the webinar.
USDA also released the following Q&As:
Hemp Production Program Questions and Answers
Question 1: Why is the Department of Agriculture building a marketing program for the commercial production of hemp in the United States?
The 2018 Farm Bill (the Agriculture Improvement Act of 2018) directed USDA to develop a program by which it will review and approve plans submitted by each state, territory and Indian tribal agency outlining their production of hemp for commercial uses.
Question 2: What is the purpose of the production plans?
Each state, territory and tribal agency’s plan will provide details on practices and procedures that enable hemp producers in their jurisdiction to operate according to their individual plan and in compliance with federal laws.
Question 3: Who can submit production plans to USDA for consideration?
The 2018 Farm Bill authorizes state departments of agriculture, including agencies representing the District of Columbia, the Commonwealth of Puerto Rico, any other territory or possession of the United States, and Indian tribal governments, to submit plans to USDA for consideration.
Question 4: What should each plan include?
As required by Sec. 297B of the Farm Bill, each plan must describe: (1) a practice to maintain relevant information regarding land on which hemp is produced in the state or territory of the Indian tribe; (2) a procedure for testing, using post-decarboxylation or other similarly reliable methods, delta-9 tetrahydrocannabinol concentration to ensure levels are not more than .3% on a dry matter basis in hemp produced in the state or territory of the Indian tribe; (3) a procedure for the effective disposal of plants and products produced in violation of this subtitle; (4) a procedure to comply with law enforcement procedures; (5) a procedure for conducting annual inspections of hemp producers; (6) a procedure for submitting information on hemp producers to USDA; and (7) a certification that the state or Indian tribe has the resources and personnel to carry out the practices and procedures described above.
Question 5: How should state, territory and Indian tribal agencies submit their plans to USDA?
USDA accepts plans via email or postal mail. State departments of agriculture, including agencies representing the District of Columbia, the Commonwealth of Puerto Rico, any other territory or possession of the United States, and Indian tribal governments, may submit their plans to the USDA Agricultural Marketing Service Specialty Crops Program using:
Postal mail: Deputy Administrator
Specialty Crops Program
USDA Agricultural Marketing Service
1400 Independence Avenue SW Room 2077-S, Stop 0235 Washington, D.C. 20250-0235
Question 6: When can growers begin planting hemp in compliance with the authorities of the 2018 Farm Bill?
Until the USDA regulation is finalized and published in the Federal Register, research and development initiatives authorized in the 2014 Farm Bill remain in effect.
Question 7: How can groups and individuals learn more about activities related to USDA’s development of regulations for the commercial production of hemp?
USDA has provided additional information on its website and will continue to update resources for both the public and industry. In addition, USDA has scheduled a listening session for March 13, 2019, to provide the public an opportunity to present suggestions on various aspects of the regulations under development.
Question 8: In instances when a state or Indian tribe does not submit a plan to USDA, can individual producers in those states or Indian tribes submit production plans on their own behalf to USDA for consideration?
Yes, if the production of hemp is not otherwise prohibited by the state or Indian tribe, the 2018 Farm Bill authorizes USDA to accept production plans from individual producers in the process of licensing them to operate according to future regulations. In those instances, individual producers would be subject to a plan established by the federal government. USDA encourages individual producers to engage with their state agency or Tribal government prior to submitting individual plans to USDA to avoid duplicate submissions.
The Food and Drug Administration will hold its first public hearings on CBD in April as the agency weighs rules allowing companies to add the popular cannabis-based compound to food, Commissioner Scott Gottlieb said Wednesday. “We’re deeply focused on this. We have taken on other hard challenges before,” Gottlieb told the House Appropriations Committee on Wednesday. “You have my commitment I’m focused on this one.” Gottlieb said he has heard Congress “loud and clear” when it legalized hemp products, including CBD, in December and is putting together a working group of senior officials to work on the new rules. The FDA will kick off its rulemaking process with a public hearing in April, he said. However, Gottlieb warned the committee that it will not be a “straightforward” process.
Given the results of this study, it would seem to confirm that full-spectrum extract is preferable over CBD isolate for most CBD users, but CBD isolate is still frequently used and believed by some to be more effective than full-plant extract. This belief is led by the idea that CBD is the only medically sought after cannabinoid in the cannabis plant, aside from THC. Many CBD isolate users are under the impression that by consuming only the CBD cannabinoid and no terpenes or any other “unnecessary” components of the plant, they are getting a more powerful or effective dose of CBD. When vaping a CBD extract, which as stated previously, is considered to be the most efficient and quick-acting method of administering CBD, isolate users may feel that they are taking the most efficient route to CBD consumption. While this method might be efficient, the lack of entourage effect means the benefits are reduced when compared to full-spectrum CBD consumption.
However, CBD isolate does have something to offer CBD users that full-spectrum extracts does not. The fact that full-spectrum extracts invariably contain low levels of THC means that some users prefer to play it safe and stick to pure CBD by itself, out of fear of failing a drug test or experiencing a form of “high”, although both of these occurrences have been found to be fairly unlikely.
THC is one of the cannabinoids involved in the “entourage effect” stated earlier so it is ideal for inclusion in CBD supplementation. A recent article on full-spectrum CBD demonstrates the importance of THC inclusion by stating, “In hemp THC is a minor constituent and appears only in trace amounts under 0.03% by dry weight, as required by the U.S. government for hemp products. THC mimics the action of anandamide, a neurotransmitter naturally produced in the human body, and binds to CB1 receptors in the endocannabinoid system found mostly in the brain. The extremely low levels of THC in hemp make hemp oil non-psychoactive and safe for all ages to use.”
The wide range of benefits contained in full-spectrum CBD extracts means some CBD merchants have either ceased to sell, or scale down the promotion of CBD isolate, in comparison to the whole-plant extract variety. Companies and individuals who extract CBD themselves are realising that cannabis has more to offer medicinally than just CBD or THC, and that there is little to no reason to not include all that this “super-plant” has to offer in the extraction process.
This all serves to underline the importance of testing CBD extract for the various levels of active ingredients. If your homemade CBD extract contains a high amount of THC it could be illegal in your country and require you use either a different method of extraction, or more likely, the need to find a source of hemp that has lower THC. As more scientific literature emerges supporting the entourage effect, and increased benefits of full-spectrum CBD compared to CBD isolate, we can expect the manufacture and sale of CBD goods based around isolate to greatly reduce in the coming years.